Juan Pulido, MD
Pulmonary Disease · Jacksonville Beach, FLNPI 1336293620
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,477 of the $130,181 with a category attached, or 71.0%. Actelion Pharmaceuticals US, Inc. accounts for 85.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $41,252 and has fallen 58.8% since, to $16,990 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $406.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$111K
- Fisher & Paykel Healthcare Inc$15K
- AstraZeneca$2K
- Merck$462
- Edwards Lifesciences$419
- Boehringer Ingelheim$300
- plus $2K from 21 others
Across 21 payments — averaging $21,805 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$367K
- Medtronic$55K
- AstraZeneca$27K
- Actelion Pharmaceuticals, Ltd$6K
- Partner Therapeutics, Inc.$2K
What the payments were for
- Speaking & faculty fees$92,47771%
- Travel & lodging$27,62321%
- Food & beverage$9,9178%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 176 | $110,822 |
| Fisher & Paykel Healthcare Inc | 18 | $14,682 |
| AstraZeneca | 47 | $1,575 |
| Merck | 8 | $462 |
| Edwards Lifesciences | 3 | $419 |
| Boehringer Ingelheim | 15 | $300 |
| Amgen | 6 | $243 |
| GSK | 13 | $216 |
| Insmed, Inc. | 5 | $205 |
| Inari Medical, Inc. | 1 | $185 |
| Baxter Healthcare | 8 | $165 |
| Nxstage Medical, Inc. | 1 | $142 |
| W. L. Gore & Associates, Inc. | 1 | $141 |
| Abbott | 1 | $130 |
| Verona Pharma, Inc. | 1 | $125 |
| Avanos Medical | 1 | $74 |
| Sanofi | 2 | $46 |
| Philips North America LLC | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $32 |
| Boston Scientific | 1 | $31 |
| ERBE USA Inc | 1 | $30 |
| Medtronic(2 entities) | 2 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$96,634
- OPSUMIT$92,169
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$12,154
- PT100US/myAIRVO 2$2,275
- PT101US/AIRVO2$2,275
- OPT944/Optiflow Nasal Cannula Medium 20Pack$2,275
- OPT970/Optiflow Tracheostomy interface 20pack$2,275
- 900PT561/Air Spiral Breathing Tube Chamber kit$2,275
- WINREVAIR$361
- FASENRA$238
- FLOWTRIEVER CATHETER, S$185
- CT THROMBECTOMY SYSTEM KIT$185
- SAPIEN 3 Ultra RESILIA$165
- NXSTAGE SYSTEM ONE$142
- GORE PROPATEN Vascular Graft$141
- HemoSphere$131
- FREESTYLE LIBRE 3$130
- Ohtuvayre$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$123
- TEZSPIRE$122
How this compares
$130,181 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 25 | $317,049 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $151,580 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,043 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,909 |
| Tadalafil | 17 | $6,777 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,129 |
| Montelukast Sodium | 26 | $426 |
| Famotidine | 12 | $234 |
| Pantoprazole Sodium | 13 | $112 |
| Methylprednisolone | 11 | $63 |
| Prednisone | 16 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $110,822 | $317,04925 claims |
| GSKTrelegy Ellipta | $216 | $151,580133 claims |
| AstraZenecaBreztri Aerosphere | $1,575 | $14,04317 claims |
| Boehringer IngelheimSpiriva Respimat | $300 | $10,90917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville Beach
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.